TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18452826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PSA with other markers or tests
Study: 11866009
Drug: Nacystelyn (NAL)
Normalized name: Nacystelyn
DrugBank: Nacystelyn (DB17839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nacystelyn (NAL) 24 mg (12 puffs)
Study: 11866009
Drug: Nacystelyn (NAL)
Normalized name: Nacystelyn
DrugBank: Nacystelyn (DB17839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nacystelyn (NAL) (4 mg to 16 mg, varying doses)
Study: 8829889
Drug: Aceclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac (100 mg b.i.d.)
Study: 10791619
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg t.i.d.)
Study: 326265
Drug: Ditenate Tetra
Normalized name: tetracycline hydrochloride Oral Capsule [Tetra 500]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ditenate Tetra (combination of tetracycline, theophylline, doxylamine succinate, etafedrine, phenylephrine, and guaifenesine)
Study: 29275919
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg melatonin (2 melatonin capsules, 5 mg each)
Study: 20007932
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment (n = 178)
Study: 20007932
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (n = 181)
Study: 12152002
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin for 7 days
Study: 12152002
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin for 7 days
Study: 12152002
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 30 mg lansoprazole and 750 mg amoxicillin for 7 days without clarithromycin
Study: 12152002
Drug: H pylori-positive
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori-positive patients given 400 mg/day clarithromycin
Study: 12152002
Drug: H pylori-positive
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori-positive patients given 800 mg/day clarithromycin
Study: 12152002
Drug: Both patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both patient groups (200 mg and 400 mg clarithromycin)
Study: 10527181
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d of risedronate
Study: 11185630
Drug: hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide 25 mg
Study: 27599667
Drug: amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 10 mg
Study: 2185158
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g daily for 5 days
Study: 2185158
Drug: Oral penicillin
Normalized name: penicillin G Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral penicillin 1 million units 3 times daily for 12 days
Study: 1829514
Drug: Oral penicillin
Normalized name: penicillin G Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral penicillin
Study: 31531960
Drug: Immediate-release prednisolone
Normalized name: prednisolone Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release prednisolone (IR)
Study: 28243723
Drug: PBM-LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM-LED therapy
Study: 26209223
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy (HT) continuation
Study: 26209223
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy (HT) discontinuation
Study: 25502511
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta 1 mg/kg biweekly
Study: 19954719
Drug: Tacrolimus (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (3 mg/day, 0.04 - 0.075 mg/kg)
Study: 17578464
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 2 microg/kg
Study: 15187493
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril and candesartan
Study: 22011217
Drug: EE/DRSP (ethinyl-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/DRSP (ethinyl-estradiol 30 mcg/drospirenone 3 mg)
Study: 22011217
Drug: EE/CMA (ethinyl-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/CMA (ethinyl-estradiol 30 mcg/chlormadinone acetate 2 mg)
Study: 21056810
Drug: C(et) of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: C(et) of remifentanil 0.5 ng/mL
Study: 21056810
Drug: C(et) of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: C(et) of remifentanil 1 ng/mL
Study: 21056810
Drug: C(et) of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: C(et) of remifentanil 1.5 ng/mL
Study: 17985581
Drug: Magnesium group
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium group 1 (Mg1 G) - 50 mg kg(‐1) preoperatively followed by 8 mg kg(‐1) h(‐1) infusion
Study: 17985581
Drug: Magnesium group
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium group 2 (Mg2 G) - 50 mg kg(‐1) preoperatively followed by 16 mg kg(‐1) h(‐1) infusion
Study: 17985581
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - isotonic solution
Study: 15659503
Drug: Attenuated-dose (AD)
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated-dose (AD) regimen: cisplatin 25 mg/m² on days 1 and 2, etoposide 60 mg/m² on days 1, 2, and 3 every 3 weeks.
Study: 15659503
Drug: Full-dose (FD)
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose (FD) regimen: cisplatin 40 mg/m² on days 1 and 2, etoposide 100 mg/m² on days 1, 2, and 3 every 3 weeks, plus lenograstim 5 mg/kg days 5 through 12, every 3 weeks.
Study: 12477996
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (160 mg twice per day oral suspension)
Study: 2317419
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction with isoflurane and rectal thiopentone premedication
Study: 2317419
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction with isoflurane without premedication
Study: 2317419
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction with halothane and rectal thiopentone premedication
Study: 2317419
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction with halothane without premedication
Study: 6773613
Drug: Propranolol 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 480 mg/day
Study: 6773613
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propranolol and nifedipine
Study: 28285571
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment using visual imagery under conditions of rote repetition and spaced retrieval
Study: 28285571
Drug: No-treatment attention
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment attention control
Study: 28285571
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment using visual imagery
Study: 26402079
Drug: 2.3 g
Normalized name: Urea 2.3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.3 g ω3 FA daily for 6 months
Study: 23733403
Drug: Extended-release memantine
Normalized name: memantine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release memantine (28 mg, once daily)
Study: 19515737
Drug: Lignan supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignan supplements
Study: 17088453
Drug: Acipimox (inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (inhibitor of lipolysis)
Study: 15474700
Drug: Picotamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (600 mg bid)
Study: 15474700
Drug: Aspirin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (320 mg od)
Study: 11197402
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide at 20 ppm
Study: 9232132
Drug: Alfentanil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously)
Study: 9232132
Drug: Alfentanil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously) with rifampin induction
Study: 9232132
Drug: Alfentanil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously) with troleandomycin inhibition
Study: 8007760
Drug: Cocaine hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine hydrochloride (10 mg unit doses, intranasally)
Study: 31229240
Drug: Pexidartinib (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexidartinib (1000 mg per day for 2 weeks, then 800 mg per day for 22 weeks)
Study: 21971662
Drug: L‐Ala‐Gln (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐Ala‐Gln (20% solution, 0.5g/Kg, adding saline to complete 100ml)
Study: 21971662
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (100 ml, delivered intravenously over 3 hours)
Study: 17197214
Drug: ketamine/remifentanil (KET/REMI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine/remifentanil (KET/REMI) at low REMI target concentration (1ng/ml)
Study: 17197214
Drug: placebo/remifentanil (P/REMI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/remifentanil (P/REMI) at 2ng/ml target concentration
Study: 17197214
Drug: ketamine/remifentanil (KET/REMI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine/remifentanil (KET/REMI) at 2ng/ml target concentration
Study: 15715026
Drug: Cognitive‐Behavioral Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioral Treatment (CBT Group)
Study: 11597824
Drug: Paroxetine 20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20‐40 mg
Study: 11597824
Drug: Paroxetine 20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20‐40 mg with pindolol
Study: 9150858
Drug: S‐naproxen betainate
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐naproxen betainate sodium salt monohydrate (naproxen‐betaNa), 575 mg capsule containing 342 mg of S‐naproxen
Study: 9150858
Drug: Sodium salt
Normalized name: Hepes Sodium Salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salt of S‐naproxen (reference), two 275 mg tablets containing 502 mg of S‐naproxen
Study: 8205295
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 or 5.0 mg twice daily)
Study: 3548930
Drug: Ticarcillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin/clavulanic acid (3 g ticarcillin and 100 mg clavulanic acid every 8 hours)
Study: 3548930
Drug: Metronidazole/netilmicin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole/netilmicin (500 mg metronidazole and 80 mg netilmicin every 8 hours)
Study: 25326180
Drug: Standard non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard non-surgical therapy + sham treatments (Control Group)
Study: 25326180
Drug: Standard non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard non-surgical therapy + tNMR (Treatment Group)
Study: 19239400
Drug: Injection diclofenac
Normalized name: diclofenac Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection diclofenac sodium 75 mg/ml (test formulation) given as an intradeltoid injection
Study: 19239400
Drug: Injection diclofenac
Normalized name: diclofenac Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection diclofenac sodium 75 mg/3 ml (reference formulation) given intragluteally
Study: 16439873
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg enfuvirtide, once-daily (QD)
Study: 16439873
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg enfuvirtide, twice-daily (BID)
Study: 12616182
Drug: Granisetron pretreatment
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron pretreatment (5 mL of 2 mg in 0.9% saline)
Study: 12616182
Drug: Lidocaine pretreatment
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine pretreatment (5 mL of 40 mg in 0.9% saline)
Study: 12616182
Drug: Saline pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline pretreatment (5 mL of 0.9% saline)
Study: 1474160
Drug: Fasted state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasted state (30-mg OSR tablet every 12 hours)
Study: 1474160
Drug: Fed state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed state (30-mg OSR tablet every 12 hours)
Study: 6386008
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GBE) (40 mg GBE; rökan)
Study: 30559051
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance (10 mg orally on days 1–21 of a 28‐day cycle)
Study: 26581327
Drug: Delafloxacin 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delafloxacin 50, 100, 200, 400, 800, 1200, and 1600 mg (single ascending-dose study)
Study: 26581327
Drug: Delafloxacin 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delafloxacin 250 mg (single-dose crossover study)
Study: 26581327
Drug: Delafloxacin 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delafloxacin 250 mg (parallel group study)
Study: 26581327
Drug: Delafloxacin 100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delafloxacin 100, 200, 400, 800, 1200 mg once daily for 5 days (multiple ascending-dose study)
Study: 26581327
Drug: Delafloxacin 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delafloxacin 900 mg (single-dose, randomized, 3-period crossover study)
Study: 19208560
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin plus aspirin (LMWH/ASA)
Study: 9723147
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg per day)
Study: 8039533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of omeprazole and doxycycline monohydrate
Study: 28576901
Drug: Ultrasound-guided popliteal
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided popliteal sciatic (20 mL) and saphenal nerve (8 mL) PNB with ropivacaine 7.5 mg/mL
Study: 28576901
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia (2 mL) with hyperbaric bupivacaine 5 mg/mL
Study: 23917335
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy with 2.5 % carbohydrate beverage (group A)
Study: 1827006
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg isradipine twice daily
Study: 8466715
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine retard once daily
Study: 28734623
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Clopidogrel (n=56)
Study: 28734623
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Placebo (n=57)
Study: 19113922
Drug: Phylloquinone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone (1 mg daily)
Study: 19113922
Drug: MK4 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK4 (45 mg daily)
Study: 12544375
Drug: Reboxetine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (8 to 10 mg/d)
Study: 9100582
Drug: Cyclic recombinant
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic recombinant human growth hormone (20 micrograms/kg.day) plus salmon calcitonin (100 U/day)
Study: 9100582
Drug: Cyclic recombinant
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic recombinant human growth hormone (20 micrograms/kg.day) plus placebo
Study: 9100582
Drug: Cyclic recombinant
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic recombinant human growth hormone plus placebo
Study: 9100582
Drug: Cyclic recombinant
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic recombinant human growth hormone plus salmon calcitonin
Study: 8386794
Drug: Lomefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin (400 mg orally 2‐6 h before surgery)
Study: 8386794
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g intravenously 30‐90 min before surgery)
Study: 2948534
Drug: AH23848 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH23848 (70 mg orally)
Study: 2948534
Drug: AH23848 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH23848 (70 mg three times a day for seven days)
Study: 29911511
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) sessions, three interviews per subject, performed monthly over a 3-month period
Study: 20863951
Drug: varespladib 500
Normalized name: Varespladib
DrugBank: Varespladib (DB11909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: varespladib 500 mg daily plus atorvastatin 80 mg daily
Study: 20863951
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus atorvastatin 80 mg daily
Study: 18226046
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (OGTT) at baseline and after 6 years
Study: 18226046
Drug: Weight increase,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight increase, waist-to-hip ratio, indices of insulin resistance and beta-cell function
Study: 10484538
Drug: Beta-radiation therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-radiation therapy after balloon angioplasty
Study: 1860132
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac (50 mg to 100 mg)
Study: 6311477
Drug: Enalapril (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10, 20, or 40 mg/day for 4 wk each)
Study: 27491531
Drug: Guided internet
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet cognitive-behavioural therapy (ICBT)
Study: 27491531
Drug: Unguided internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided internet cognitive-behavioural therapy (U-ICBT)
Study: 17564637
Drug: efalizumab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: efalizumab 0.5 mg/kg weekly subcutaneously for 12 weeks
Study: 17564637
Drug: efalizumab 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: efalizumab 2 mg/kg weekly subcutaneously for 12 weeks
Study: 17564637
Drug: efalizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: efalizumab (both doses)
Study: 17564637
Drug: efalizumab (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: efalizumab (higher dose)
Study: 14643816
Drug: Diazoxide (DZX)
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazoxide (DZX) group, 1.5 mg/kg diazoxide infused intravenously within 5 min followed by a 5‐min washout before CPB.
Study: 14643816
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, time‐matched period of placebo infusion.
Study: 8910173
Drug: Direct obturator
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct obturator nerve block with 15 ml of lidocaine (Group A, n = 20)
Study: 8910173
Drug: Bilateral direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral direct obturator nerve block with 30 ml of lidocaine (Group B, n = 12)
Study: 8910173
Drug: 3‐in‐1 indirect
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐in‐1 indirect obturator nerve block with 40 ml of lidocaine (Group C, n = 17)
Study: 7104161
Drug: Oral meptazinol
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meptazinol (50 mg)
Study: 7104161
Drug: Oral meptazinol
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meptazinol (100 mg)
Study: 7104161
Drug: Oral meptazinol
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meptazinol (150 mg)